Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Emerging therapeutic targets in bladder cancer.

Cancer treatment reviews - 1 Feb 2015

Carneiro Benedito A, Meeks Joshua J, Kuzel Timothy M, Scaranti Mariana, Abdulkadir Sarki A, Giles Francis J

Abstract excerpt

Treatment of muscle invasive urothelial bladder carcinoma (BCa) remains a major challenge. Comprehensive genomic profiling of tumors and identification of driver mutations may reveal new therapeutic targets. This manuscript discusses relevant molecular drivers of the malignant phenotype and agents with therapeutic potential in BCa. Small molecule pan-FGFR inhibitors have shown encouraging efficacy and safety...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aurora Kinases
Share to Carcinoma, Transitional Cell
Share to Cyclin D1

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cyclin-Dependent Kinase 4

Share to Polo-Like Kinase 1

Share to Receptor, Fibroblast Growth Factor, Type 1

Share to Trastuzumab

Share to Tuberous Sclerosis Complex 1 Protein

Source

Identifiers

PMID: 25498841
DOI: 10.1016/j.ctrv.2014.11.003

Genes

CTLA4
TSC1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Emerging therapeutic targets in bladder cancer.PMID 25498841Read ↗

Molecularly Targeted Therapy towards Genetic Alterations in Advanced Bladder CancerSemantic proximity Read ↗

New and promising strategies in the management of bladder cancer.Semantic proximity Read ↗

Management of advanced bladder cancer in the era of targeted therapies.Semantic proximity Read ↗

Molecular targets and targeted therapies in bladder cancer managementSemantic proximity Read ↗

Beyond conventional chemotherapy: Emerging molecular targeted and immunotherapy strategies in urothelial carcinoma.Semantic proximity Read ↗

FGFR3 alterations in bladder cancer: Sensitivity and resistance to targeted therapies.Semantic proximity Read ↗

Genomic and Therapeutic Landscape of Non-muscle-invasive Bladder Cancer.Semantic proximity Read ↗

Autocrine Signaling by Receptor Tyrosine Kinases in Urothelial Carcinoma of the BladderSemantic proximity Read ↗

Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy.Semantic proximity Read ↗

FGFR Inhibitors in Urothelial Cancer: From Scientific Rationale to Clinical Development.Semantic proximity Read ↗

Therapeutically actionable PAK4 is amplified, overexpressed and involved in bladder cancer progressionSemantic proximity Read ↗

Precision medicine for urothelial bladder cancer: update on tumour genomics and immunotherapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.